Приобретенное удлинение интервала QT у спортсменов
https://doi.org/10.47529/2223-2524.2021.4.3
Аннотация
Синдром удлиненного синдрома QT (LQTS) — часто встречаемое нарушение состояния, приводящее к драматичным для пациентов исходам, главным из которых является внезапная сердечная смерть. В данном обзоре представлены подробные данные о диагностике, распространенности, классификации, этиологии. Многообразие причин, приводящих к LQTS, создает сложности в дифференциальной диагностике этого состояния, и в итоге LQTS часто остается за пределами внимания врачей, осуществляющих контроль состояния здоровья спортсменов. Особое внимание уделено приобретенным формам LQTS, в частности лекарственноиндуцированной форме. Изложены результаты исследований, направленных на изучение распространенности LQTS и влияние лекарственных препаратов на интервал QT. Подробно рассмотрено влияние на интервал QT нестероидных противовоспалительных средств, поскольку они часто используются спортсменами. Цель данного обзора — расширить понимание этиологии LQTS и обосновать необходимость тщательного ЭКГскрининга и фармакологического контроля у спортсменов.
Ключевые слова
Об авторах
А. С. ЮнисоваРоссия
Юнисова Алина Саидовна, аспирант кафедры спортивной медицины
105122, Россия, Москва, Сиреневый бульвар, 4
А. В. Смоленский
Россия
Смоленский Андрей Вадимович, д.м.н., профессор, заведующий кафедрой спортивной медицины
105122, Россия, Москва, Сиреневый бульвар, 4
Список литературы
1. Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: Tis document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077–1109. https://doi.org/10.1093/europace/eur245
2. Ackerman M.J. Long QT syndrome and sports participation: oil and water or an acceptable and manageable combination? JACC Clin. Electrophysiol. 2015;1(1–2):71–73. https://doi.org/10.1016/j.jacep.2015.03.009
3. Adler A., vander Werf C., Postema P.G., Rosso R., Bhuiyan Z.A., Kalman J.M., et al. Tephenomenon of ‘QT stunning’: Te abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9(6):901–908. https://doi.org/10.1016/j.hrthm.2012.01.026
4. Bazett H.C. An analysis of timerelations of electrocardiograms. Heart. 1920;7:353–370.
5. Border W.L., Benson D.W. Sudden infant death syndrome and long QT syndrome: the zealots versus the naysayers. Heart Rhythm. 2007;4(2):167–169. https://doi.org/10.1016/j.hrthm.2006.12.019
6. Klivinyi C., Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J. Pain. 2018;31(1):3–9. https://doi.org/10.3344/kjp.2018.31.1.3
7. Corrado D., Basso C., Pavei A., Michieli. P., Schiavon M., Tiene G. Trends in sudden cardiovascular death in young competitive athletes afer implementation of a preparticipation screening program. JAMA. 2006; 296(13):1593–1601. https://doi.org/10.1001/jama.296.13.1593
8. Corrado D., Pelliccia A., Bjornstad H.H., Vanhees L., Biffi A., Borjesson M., et al. Cardiovascular preparticipation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Eur. Heart J. 2005;26(5): 516–524. https://doi.org/10.1093/eurheartj/ehi108
9. Corrado D., Basso C., Schiavon M., Tiene G. Screening for hypertrophic cardiomyopathy in young athletes. N. Eng. J. Med. 1998;339(6):364–369. https://doi.org/10.1056/NEJM199808063390602
10. Pelliccia A., Sharma S., Gati S., Bäck M., Börjesson M., Caselli S., et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur. Heart J. 2021;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605
11. Digby G.C., Perez Riera A.R., Barbosa Barros R., Simpson C.S., Redfearn D.P., Methot M., et al. Acquired Long QT Interval: A Case Series of Multifactorial QT Prolongation. Clin. Cardiol. 2011;34(9):577–582. https://doi.org/10.1002/clc.20945
12. Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment. J. Clin. Endocrinol. Metab. 2011;96(10):3020–3030. https://doi.org/10.1210/jc.20111048
13. Meyer T., Ruppert V., Karatolios K., Maisch B. Hereditary long QT syndrome due to autoimmune hypoparathyroidism in autoimmune polyendocrinopathycandidiasisectodermal dystrophy syndrome. J. Electrocardiol. 2007;40(6):504–509. https://doi.org/10.1016/j.jelectrocard.2006.12.013
14. Michels G., Kochanek M., Pfster R. Lifethreatening cardiac arrhythmias due to druginduced QT prolongation. Med. Klin. Intensivmed. Notfmed. 2016;111(4):302–309. https://doi.org/10.1007/s0006301500716
15. Mitchell J.H., Haskell W.L., Raven P.B. Classifcation of sports. J. Am. Coll Cardiol. 1994; 24(4):864–866. https://doi.org/10.1016/07351097(94)908419
16. Molokhia M., Pathak A., Lapeyre-Mestre M., Caturla L., Montastruc J L., L’Association Française des Centres Régionaux de Pharmacovigilance (CRPV), ase ascertainment and estimated incidence of druginduced longQT syndrome: Study in Southwest France. Br. J. Clin Pharmacol. 2008;66(3):386–395. https://doi.org/10.1111/j.13652125.2008.03229.x
17. Moss A.J. Long QT syndrome. JAMA. 2003;289(16):2041–2044. https://doi.org/10.1001/jama.289.16.2041
18. Moss A.J., Schwartz P.J., Crampton R.S., Tzivoni D., Locati E.H., MacCluer J., et al. Te long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84(3):1136–1144. https://doi.org/10.1161/01.cir.84.3.1136
19. Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efcient approach to genotyping in clinical practice. JAMA. 2005;294(23):2975–2980. https://doi.org/10.1001/jama.294.23.2975
20. Newman D.B., Fidahussein S.S., Kashiwagi D.T., Kennel K.A., Kashani K.B., Zhen Wang, et al. Reversible cardiac dysfunction associated with hypocalcemia: a systematic review and metaanalysis of individual patient data. Heart Fail. Rev. 2014;19(2):199–205. https://doi.org/10.1007/s1074101393711
21. Pathak A., Boveda S., Defaye P., Mansourati J., Mallaret M., Tebault L., et al. Celecoxibassociated torsade de pointes. Ann Pharmacother. 2002;36(7–8):1290–1291. https://doi.org/10.1345/aph.1A429
22. Pelliccia A., Fagard R., Bjørnstad H.H., Anastassakis A., Arbustini E., Assanelli D., et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005;26(14):1422–1445. https://doi.org/10.1093/eurheartj/ehi325
23. Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316
24. Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk Stratifcation in the LongQT Syndrome. N. Engl. J. Med. 2003;348(19):1866–1874. https://doi.org/10.1056/nejmoa022147
25. Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berul C., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):e85–e108. https://doi.org/10.1016/j.hrthm.2013.07.021
26. Kim J.A., Chelu M.G. Inherited Arrhythmia Syndromes. Tex Heart Inst J. 2021 Sep 1;48(4):e207482. https://doi.org/10.14503/THIJ207482.
27. Nakano Y., Shimizu W. Genetics of longQT syndrome. J. Hum. Genet. 2016;61(1):51–55. https://doi.org/10.1038/jhg.2015.74
28. Rajab A., Straub V., McCann L.J., Seelow D., Varon R., Barresi R., et al. Fatal cardiac arrhythmia and longQT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRFCAVIN mutations. PLoS Genet. 2010;6(3):e1000874. https://doi.org/10.1371/journal.pgen.1000874
29. Roden D.M. Predicting druginduced QT prolongation and torsades de pointes. J. Physiol. 2016;594(9):2459–68. https://doi.org/10.1113/JP270526
30. Basavarajaiah S., Wilson M., Whyte G., Shah A., Behr E., Sharma S. Prevalence and signifcance of an isolated long QT interval in elite athletes. Eur. Heart J. 2007;28(23):2944–2949. https://doi.org/10.1093/eurheartj/ehm404
31. Schwartz P.J., Woosley R.L. Predicting the Unpredictable: DrugInduced QT Prolongation and Torsades de Pointes. J. Am. Coll. Cardiol. 2016;67(13):1639–1650. https://doi.org/10.1016/j.jacc.2015.12.063
32. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88(2):782–784. https://doi.org/10.1161/01.cir.88.2.782
33. Schwartz P.J.,Crotti L.QTc behavior during exercise and genetic testing for the longQT syndrome. Circulation. 2011;124(20):2181–2184. https://doi.org/10.1161/CIRCULATIONAHA.111.062182
34. Sharma S., Whyte G., Elliott P., Padula M., Kaushal R., Mahon N., McKenna W.J. Electrocardiographic changes in 1000 highly trained junior elite athletes. Br. J. Sports Med. 1999;33(5):319–324. https://doi.org/10.1136/bjsm.33.5.319
35. Straus M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., van der Lei J., de Graeff P.A., et al. Noncardiac QTcprolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 2005;26(19):2007–2012. https://doi.org/10.1093/eurheartj/ehi312
36. Maury P., Delasnerie H., Beneyto M., Rollin A. Autonomic cardiac innervation: impact on the evolution of arrhythmias in inherited cardiac arrhythmia syndromes. Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):308–314. English. https://doi.org/10.1007/s00399021007743 Epub 2021 Jun 29.
37. Turan S. Current nomenclature of pseudohypoparathyroidism: inactivating parathyroid hormone / parathyroid hormonerelated protein signaling disorder. J. Clin. Res. Pediatr. Endocrinol. 2017;9(2):58–68. https://doi.org/10.4274/jcrpe.2017.s006
38. Underbjerg L., Sikjaer T., Mosekilde L., Rejnmark L. Pseudohypoparathyroidism — epidemiology, mortality and risk of complications. Clin. Endocrinol (Oxf.). 2016;84(6):904–911. https://doi.org/10.1111/cen.12948
39. Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant caveolin3 induces persistent late sodium current and is associated with longQT syndrome. Circulation. 2006;114(20):2104–2112. https://doi.org/10.1161/CIRCULATIONAHA.106.635268
40. Viskin S., Postema P.G., Bhuiyan Z.A., Rosso R., Kalman J.M., Vohra J.K., et al. Te response of the QT interval to the brief tachycardia provoked by standing: A bedside test for diagnosing long QT syndrome. J. Am. Coll. Cardiol. 2010;55(18):1955–1961. https://doi.org/10.1016/j.jacc.2009.12.015
41. World AntiDoping Agency. Prohibited List, Yanuary 2016 [Internet]. Available at: https://www.fa.com/sites/default/fles/wada2016prohibitedlisten_0.pdf (accessed April 24, 2016).
42. Wedekind H., Burde D., Zumhagen S., Debus V., Burkhardtsmaier G., Mönnig G., Breithardt G., Schulze-Bahr E. QT interval prolongation and risk for cardiac events in genotyped LQTSindex children. Eur. J. Pediatr. 2009;168(9):1107–1115. https://doi.org/10.1007/s0043100808966
43. Zipes D.P., Ackerman M.J., Estes N.A. 3rd, Grant A.O., Myerburg R.J., Van Hare G. Task Force 7: arrhythmias. J. Am. Coll. Cardiol. 2005;45(8):1354–1363. https://doi.org/10.1016/j.jacc.2005.02.014
Рецензия
Для цитирования:
Юнисова А.С., Смоленский А.В. Приобретенное удлинение интервала QT у спортсменов. Спортивная медицина: наука и практика. 2021;11(4):17-25. https://doi.org/10.47529/2223-2524.2021.4.3
For citation:
Yunisova A.S., Smolensky A.V. Acquired long QT interval in athletes. Sports medicine: research and practice. 2021;11(4):17-25. (In Russ.) https://doi.org/10.47529/2223-2524.2021.4.3